Stock Analiz

Sagimet Biosciences Inc. SGMT

Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026

$10.22Market cap $729M
Open the interactive analysis →

Sagimet Biosciences Inc. (SGMT) is a healthcare company listed in the US with a market value of about $729M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -32%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Sagimet Biosciences

Sagimet Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. It was profitable in 0 of the last 4 years in our data. Its share count rose by 17420% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B3.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1393.8%
ROIC (5-yr avg.)-31.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue——$2M—
Net income-$51M-$46M-$28M-$30M
Free cash flow————
EPS (diluted)$-1.58$-1.45$-2.66$-165.20
Net margin——-1393.8%—
ROIC-40.3%-27.6%-26.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 11 analysts is $27.27, 167% above the current price; targets range from $7.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $-1.24 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sagimet Biosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sagimet Biosciences pay a dividend?

Not currently.

Is Sagimet Biosciences a good stock to buy?

We do not give buy or sell advice. Sagimet Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.